Interview with John Norman, Country Manager, Nycomed South Africa
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
Address: 1 Libertas Road
Cnr Main Road and Sloane Street
Bryanston, Johannesburg
2191,South Africa
Tel: +27 (0) 11 514 3000
Web: http://www.takeda.co.za/za/
The South African arm of Nycomed has its origins in 1996 when two German companies, Byk Gulden and Madaus AG entered into a joint venture in South Africa and Byk Madaus was created. All products were managed in one combined portfolio and came from either Byk Gulden, Madaus or were in-licenced from other companies. Packaging, warehousing and distribution operations were carried out at a warehouse facility in Midrand.
In 2001, the company outsourced its distribution to PHD.
In 2002, Altana Pharma was launched when Altana bought out the Byk portion of the Byk Madaus joint venture.
In 2003 a further name change took place and the company became the South African joint venture known as Altana Madaus. It was during this period that a separate OTC and Rx division were launched, the Midrand facility was sold and the company moved from Midrand to Woodmead.
In 2007 Nycomed GmbH acquired Altana Pharma and Rottapharm acquired Madaus GmbH. A further name change took place and the local company became known as Nycomed Madaus.
In 2008, Nycomed GmbH acquired the Madaus 50% share of the joint venture and the South African business now falls under the sole control of the Nycomed group of companies.
The South African product range encompasses both licensed and in-licensed OTC (Over the Counter) and Rx (prescription) products. These products are marketed and distributed nationally.
The Rx* product range covers the following treatment areas:
Respiratory
Anti-Epileptic
Urinary Tract
Iron
Liver
Gastro Intestinal
Pain and Inflamation
* In terms of South African legislation, scheduled products may not be marketed to the public and the brands have therefore not been mentioned on this website
The OTC product range encompasses the following treatment areas and products:
Laxatives – Agiolax® and Agiobulk®
Tranquiliser – Biral®
Pain and Inflammation – Empaped®, Reparil®, Dona®
Vitamin and Mineral – Emvit®, Emvit®.M, Emvit® Cal-D3, Magnesit®
Iron – Ferrimed®
Sun care – Piz Buin®
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
David Mukanga of the Bill and Melinda Gates Foundation gives an overview of the latest developments on the long road towards the creation of an African Medicines Agency and the…
Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind the establishment of these institutions,…
Medicines for Africa’s Lenias Hwenda highlights the vast gaps in COVID-19 vaccine access globally, especially in Africa where just six percent of the population has been vaccinated. Hwenda argues that…
Three months after the World Bank announced a EUR 600 million loan to South Africa’s Aspen Pharmacare, the African continent has received more good news as it seeks to increase…
In a notable first, following successful pilot immunisation programmes in Ghana, Kenya and Malawi, the World Health Organization (WHO) has recommended that the RTS,S malaria vaccine be rolled out across…
A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock Ingram’s full year profit drop, and Entos Pharma’s approval for Phase II clinical rials…
With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and France – has intervened to loan South African…
The latest from South African pharma, including President Ramaphosa’s blunt criticism of Big Pharma, Aspen’s reception of USD 700 million in international financial aid, Adcock Ingram’s disappointing results as fewer…
South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share…
See our Cookie Privacy Policy Here
